Author:
Lara P. Espinosa,Muiño C. Bueno,Spéville B. Doger de,Reyes J. Jiménez
Subject
Dermatology,Histology,Pathology and Forensic Medicine
Reference10 articles.
1. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity;Wilhelm;Int J Cancer J Int Cancer.,2011
2. European Medicines Agency. Stivarga (regorafenib) [Internet] htttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002573/human_med_001684.jsp&mid=WC0b01ac058001d124. Accessed November 21, 2014.
3. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: A meta-analysis;Belum;Invest New Drugs.,2013
4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet.,2013
5. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor;Autier;Arch Dermatol.,2008
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献